Long-acting injectable (LAIs) delivery systems sustain the drug therapeutic action in the
body, resulting in reduced dosage regimen, toxicity, and improved patient compliance. Lipid …

Introduction Poor or inconsistent adherence to daily oral pre-exposure prophylaxis (PrEP)
has emerged as a key barrier to effective HIV prevention. The advent of potent long-acting …

Adherence to daily oral antiretroviral therapy (ART) is a barrier to both treatment and
prevention of human immunodeficiency virus (HIV) infection. To overcome limitations of life …

The Oral route of administration forms the heartwood of the ever-growing tree of drug
delivery technology. It is one of the most preferred dosage forms among patients and …

Mortality rate of patients infected with HIV-1 has been significantly reduced by using HAART.
However, the virus to date has not been eradicated. Transmission of HIV-1 infection through …

Achieving ultra-long-term release of hydrophilic drugs over several months remains a
significant challenge for existing long-acting injectables (LAIs). Existing platforms, such as in …

Despite the world's combined efforts, human immunodeficiency virus (HIV), the causative
agent of AIDS, remains one of the world's most serious public health challenges. High …

Although hydrophilic drugs represent a large proportion of all therapeutics used to treat and
manage chronic diseases, achieving their ultra-long-term delivery via an injectable system …